Evercore analyst Vijay Kumar maintains $Medtronic (MDT.US)$ with a buy rating, and adjusts the target price from $100 to $104.
According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
There is curiosity about whether the recent uptrend in medical technology stocks is sustainable as companies approach their third-quarter financial disclosures. The sentiment heading into earnings season is tinged with caution, given that the third quarter is traditionally challenging for the MedTech sector, with a particular focus on the outlook for 2025. Additionally, forthcoming commentary about projections for the next year might temper stock price movements in the short term.
In the MedTech sector, trends toward sustained utilization into the third quarter and a strong capital expenditure forecast for the upcoming year are observed. The life science tools segment is expected to see improvements in bioprocess trends in the latter half of the year, although there is ongoing discussion regarding the prospects for instrument sales and the impact of Chinese economic measures, given the recent performance of stocks in this area. Furthermore, Medtronic, among others in the sector, is being recognized for its potential performance leading into the third quarter financial results.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析师Vijay Kumar维持$美敦力 (MDT.US)$买入评级,并将目标价从100美元上调至104美元。
根据TipRanks数据显示,该分析师近一年总胜率为57.6%,总平均回报率为5.6%。
此外,综合报道,$美敦力 (MDT.US)$近期主要分析师观点如下:
随着各公司接近第三季度财务披露,医疗科技股最近的上涨趋势是否可持续,人们对此感到好奇。鉴于第三季度传统上对医疗科技行业具有挑战性,特别关注2025年的前景,进入财报季的情绪略显谨慎。此外,即将发表的关于明年预测的评论可能会在短期内缓和股价的走势。
在医疗技术领域,可以观察到第三季度的持续利用趋势,以及对来年的强劲资本支出预测。生命科学工具板块的生物工艺趋势预计将在下半年有所改善,尽管鉴于该领域股票的近期表现,有关仪器销售前景和中国经济措施的影响的讨论仍在继续。此外,美敦力以及该行业的其他公司因其在第三季度财务业绩之前的潜在表现而获得认可。
提示:
TipRanks为独立第三方,提供金融分析师的分析数据,并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议,仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级,分析师星级代表分析师所有推荐的过往表现,通过分析师的总胜率和平均回报率综合计算得出,星星越多,则该分析师过往表现越优异,最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否,取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合,并根据评级变化对组合进行调整,在近一年中该投资组合所获得的回报率。